Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Research & Development (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Research & Development data on record, last reported at $23.0 million in Q3 2025.

  • For Q3 2025, Research & Development fell 37.68% year-over-year to $23.0 million; the TTM value through Sep 2025 reached $110.8 million, down 40.55%, while the annual FY2024 figure was $167.8 million, 11.51% down from the prior year.
  • Research & Development reached $23.0 million in Q3 2025 per ZNTL's latest filing, down from $27.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $51.6 million in Q4 2023 and bottomed at $23.0 million in Q3 2025.
  • Average Research & Development over 4 years is $40.5 million, with a median of $42.7 million recorded in 2023.
  • Peak YoY movement for Research & Development: increased 26.94% in 2023, then crashed 45.05% in 2025.
  • A 4-year view of Research & Development shows it stood at $40.6 million in 2022, then rose by 26.94% to $51.6 million in 2023, then plummeted by 36.05% to $33.0 million in 2024, then crashed by 30.4% to $23.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $23.0 million in Q3 2025, $27.6 million in Q2 2025, and $27.2 million in Q1 2025.